Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P84090
UPID:
ERH_HUMAN
Alternative names:
-
Alternative UPACC:
P84090; B2R5H2; P70659; Q14259
Background:
The Enhancer of rudimentary homolog, identified by its unique accession number P84090, plays a pivotal role in cellular processes, potentially influencing the cell cycle. This protein, through its regulatory functions, may impact cell division and growth, highlighting its importance in cellular biology.
Therapeutic significance:
Understanding the role of Enhancer of rudimentary homolog could open doors to potential therapeutic strategies. Its involvement in the cell cycle suggests a foundational role in cellular proliferation and stability, making it a target of interest for drug discovery efforts aimed at regulating cell growth in diseases.